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Aims The effects of serelaxin, a recombinant form of human relaxin-2 peptide, on vascular function in the coronary mi-
crovascular and systemic macrovascular circulation remain largely unknown. This mechanistic, clinical study assessed
the effects of serelaxin on myocardial perfusion, aortic stiffness, and safety in patients with stable coronary artery
disease (CAD).
....................................................................................................................................................................................................
Methods
and results
In this multicentre, double-blind, parallel-group, placebo-controlled study, 58 patients were randomized 1:1 to 48 h
intravenous infusion of serelaxin (30 mg/kg/day) or matching placebo. The primary endpoints were change from
baseline to 47 h post-initiation of the infusion in global myocardial perfusion reserve (MPR) assessed using adeno-
sine stress perfusion cardiac magnetic resonance imaging, and applanation tonometry-derived augmentation index
(AIx). Secondary endpoints were: change from baseline in AIx and pulse wave velocity, assessed at 47 h, Day 30,
and Day 180; aortic distensibility at 47 h; pharmacokinetics and safety. Exploratory endpoints were the effect on
cardiorenal biomarkers [N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T
(hsTnT), endothelin-1, and cystatin C]. Of 58 patients, 51 were included in the primary analysis (serelaxin, n= 25;
placebo, n= 26). After 2 and 6 h of serelaxin infusion, mean placebo-corrected blood pressure reductions of
-9.6 mmHg (P= 0.01) and -13.5 mmHg (P= 0.0003) for systolic blood pressure and -5.2 mmHg (P= 0.02) and
-8.4 mmHg (P= 0.001) for diastolic blood pressure occurred. There were no between-group differences from base-
line to 47 h in global MPR (-0.24 vs. -0.13, P= 0.44) or AIx (3.49% vs. 0.04%, P= 0.21) with serelaxin compared with
placebo. Endothelin-1 and cystatin C levels decreased from baseline in the serelaxin group, and there were no clini-
cally relevant changes observed with serelaxin for NT-proBNP or hsTnT. Similar numbers of serious adverse events
were observed in both groups (serelaxin, n= 5; placebo, n= 7) to 180-day follow-up.
....................................................................................................................................................................................................
Conclusion In patients with stable CAD, 48 h intravenous serelaxin reduced blood pressure but did not alter myocardial
perfusion.
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1. Introduction
Serelaxin is a relaxin receptor agonist and recombinant form of the natu-
rally occurring vasoactive human relaxin-2 peptide hormone.1 Relaxin
plays a central role in haemodynamic and renal adaptations to preg-
nancy.2,3 Serelaxin mediates its effects through binding to its cognate re-
ceptor, relaxin/insulin-like family peptide receptor 1 (RXFP1). Serelaxin
is pleiotropic with vasodilatory, anti-fibrotic, and end-organ protective
effects.4–6 Pharmacological effects include increased nitric oxide and vas-
cular endothelial growth factor production, inhibition of endothelin-1
and angiotensin II, and up-regulation of matrix metalloproteinases. These
effects lead to endothelial-dependent arterial vasodilatation, increased
arterial compliance, and other potentially favourable effects on cardiore-
nal haemodynamics.5,6
In the RELAX-AHF trial, intravenous (IV) serelaxin infusion was asso-
ciated with an improvement in dyspnoea and a reduction in the risk of
cardiovascular death at 6 months in patients hospitalized for acute heart
failure (AHF).1 A subsequent larger trial, RELAX-AHF-2, reported neu-
tral effects of serelaxin on in-hospital worsening of heart failure (HF) to
Day 5 and on cardiovascular mortality at 180-day follow-up.7 Coronary
artery disease (CAD) is the most common comorbidity in patients with
AHF, and in the majority of patients CAD is the underlying aetiology of
HF.8 The high prevalence of CAD in patients with AHF is evident in large
clinical trial populations,9–11 including the RELAX-AHF and RELAX-
AHF-2 cohorts (52% and 54%, respectively).1,7
Following RELAX-AHF, it was hypothesized that the beneficial effects
on outcomes seen with serelaxin may be at least partly due to improve-
ments in myocardial perfusion. Serelaxin may enhance coronary micro-
vascular and endothelial function and lead to improved myocardial
perfusion.12 Abnormal myocardial perfusion is a common finding in
patients with both ischaemic and non-ischaemic cardiomyopathy and is
prognostically relevant.13–17 Serelaxin may exert a cardioprotective ef-
fect in ischaemic–reperfusion injury, as may occur in patients with CAD
and HF.18,19 Serelaxin may improve arterial compliance, and therefore
myocardial perfusion, as coronary blood flow is dependent on aortic
driving pressure and cardiac-coronary coupling.20,21 Increased aortic
stiffness results in greater aortic reflected wave amplitude and aortic sys-
tolic blood pressure (SBP), thereby prolonging systole, reducing diastole
and leading to reduced myocardial perfusion.22,23
Given its pleiotropic mechanisms, we hypothesized that serelaxin may
enhance coronary microvascular and systemic macrovascular function.
Conversely, coronary and systemic vasodilatation secondary to serelaxin
may reduce coronary perfusion pressure, which may be clinically rele-
vant and harmful in patients with obstructive CAD. This placebo-
controlled mechanistic study investigated the acute effects of serelaxin
on myocardial perfusion and aortic stiffness; circulating biomarkers of
cardiorenal function in patients with established CAD; and overall safety
to 180-day follow-up.
2. Methods
2.1 Study design
This prospective, multicentre, double-blind, randomized, parallel-group,
placebo-controlled, phase II study was conducted in three centres across
the UK (ClinicalTrials.gov Identifier: NCT01979614) from February
2014 to February 2016. Patients were randomized 1:1 to a 48 h IV infu-
sion of serelaxin
(30lg/kg/day) or matching placebo, using a computerized randomiza-
tion system involving concealed treatment arms. The co-primary end-
points were the change from baseline in global myocardial perfusion
reserve (MPR) measured by quantitative perfusion cardiac magnetic res-
onance (CMR) imaging and the change from baseline in augmentation
index (AIx) measured by applanation tonometry. The primary endpoints
of MPR and AIx were assessed at baseline and 47 h post-
commencement of the infusion (Figure 1).
Secondary endpoints included: the change from baseline in AIx and
pulse wave velocity (PWV) assessed at the end of treatment, Day 30 and
Day 180; aortic distensibility (assessed with CMR and PWV methods) at
the end of treatment; pharmacokinetics and safety (adverse events, seri-
ous adverse events, and vital signs) of 48 h infusion of serelaxin 30lg/kg/
day. The changes in levels of circulating biomarkers of cardiorenal and
vascular function during and after treatment with serelaxin were also
assessed as part of the exploratory endpoints.
The study protocol and all amendments were reviewed by the
Independent Ethics Committee. The study was conducted according to
the ethical principles of the Declaration of Helsinki.
2.2 Participants
Male and female patients aged >_18 years who had provided written in-
formed consent were eligible for participation in this study. Inclusion cri-
teria included proven obstructive CAD, either by functional testing
(non-invasive ischaemia imaging) or anatomical imaging (invasive coro-
nary angiography or computed tomography coronary angiography).
Exclusion criteria included body weight >_160 kg, acute coronary syn-
drome within 30 days prior to screening, known significant valvular heart
disease, myocardial infarction <3 months, SBP <110 mmHg within 3 h
prior to randomization, AHF at baseline, New York Heart Association
(NYHA) Class III–IV HF, HF due to arrhythmia, women of child-bearing
potential (unless using highly effective methods of contraception during
dosing and for 3 months following study treatment), breast-feeding
women, contraindications to CMR imaging, and severe renal impairment
(estimated glomerular filtration rate < 30 mL/min/m2).
2.3 CMR acquisition and assessment
A standardized CMR protocol was acquired on 1.5 T (Siemens Avanto)
or 3.0 T (Siemens Skyra and Verio) magnetic resonance imaging (MRI)
scanners. The CMR protocol included standard localizers, long- and
short-axis cine acquisitions, stress and rest first-pass perfusion, and late
gadolinium enhancement (LGE) imaging as previously described.24 For
perfusion imaging, a saturation recovery prepared fast gradient echo se-
quence was used to acquire dynamic contrast-enhanced CMR during
adenosine stress (140–280mg/kg/min for 3 min) and rest, during first-
pass of the IV administered contrast agent (Gadovist, 0.05 mmol/kg,
5 mL/s), followed by 20 mL saline injection (5 mL/s). Three short-axis
planes through the left ventricle (basal, mid-ventricular, and apical) were
obtained.
Full left ventricular short-axis stack of cine images was acquired during
the interval between stress and rest first-pass perfusion acquisitions.
Following administration of the top-up contrast dose (Gadovist
0.05 mmol/kg), aortic cine and phase-velocity encoding sequences were
acquired at the level of the pulmonary artery bifurcation. LGE imaging
was performed with a segmented phase-sensitive inversion recovery
sequence.
CMR image collection, blinding, and handling were managed by
an independent imaging contract-research organization (CRO;
2 D. Corcoran et al.
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..VirtualScopics, Inc., Rochester, NY, USA). The CMR quantitative analy-
ses were performed by blinded academic readers with >3 years of CMR
experience (D.C., A.R., and C.B.). Cine images for ventricular volumes
and mass and myocardial perfusion images were manually contoured
(QMass, Medis, Leiden, Netherlands). Myocardial blood flow (MBF) was
derived from stress and rest perfusion images using a Fermi deconvolu-
tion method,25 implemented in MATLAB.26 Global MPR was calculated
from the ratio of global MBF evaluated at stress and at rest (MPR = stress
MBF/rest MBF). Global MBF was calculated by averaging the MBF (mL/g/
min) for basal, mid, and apical short-axis left ventricular slices. Ascending
and descending aortic strain and distensibility were derived from manu-
ally contoured end-diastolic and end-systolic aortic cine images. Aortic
strain (AS, unit free fraction) = [maximum aortic lumen area - minimum
aortic lumen area]/minimum aortic lumen area. Aortic distensibility (AD,
mmHg-1) = aortic strain/pulse pressure. Ascending aortic peak flow ve-
locity (m/s) was derived from manually contoured phase-velocity encod-
ing sequence images (QFlow, Medis, Leiden, Netherlands). The presence
or absence of myocardial scar was qualitatively assessed on the LGE
images.
2.4 Applanation tonometry assessments
The applanation tonometry assessments were performed by blinded
operators. Augmentation index [AIx = (augmentation pressure/pulse
pressure) 100], and carotid-femoral PWV were measured by applana-
tion tonometry (SphygmocorVR , AtCor Medical, Australia) at a proximal
(carotid artery) and a distal (femoral artery) site of the body, utilizing R-
wave gated determination of the time interval between the two mea-
surement points. An averaged carotid pressure waveform (from a 10 s
recording) was converted into a corresponding central waveform using
a validated transfer function (SphygmoCorVR , AtCor, Australia).27,28
2.5 Pharmacodynamics
Biomarkers reported include: N-terminal pro-brain natriuretic peptide
(NT-proBNP), high-sensitivity troponin T (hsTnT) measured to assess
myocardial safety; cystatin C measured to access renal function; the bio-
logically active form of endothelin-1 (1–21), measured to assess vascular
function. Venous blood samples were collected at 0 (pre-dose), 24, 48,
and 54 h, Day 30, and Day 180. NT-proBNP, hsTnT, and cystatin C sam-
ples were collected in EDTA tubes while endothelin-1 samples were col-
lected in EDTA tubes containing aprotinin. Plasma was immediately
frozen at -70C pending analysis in complete patient sets. Commercial
biomarker kits were as follows: hsTnT from Roche Diagnostics GmbH,
Germany; cystatin C from Gentian, Moss, Norway; and active
endothelin-1 (1–22) from Biomedica Medizinprodukte, Vienna, Austria.
2.6 Pharmacokinetic profile and
immunogenicity
Blood samples (approximately 2 mL) for pharmacokinetic (PK) evaluation
were collected at 0 (pre-dose), 24, 48, 50, and 54 h, and Day 30. Serum
serelaxin concentration was determined by an enzyme-linked immuno-
sorbent assay, developed and validated based upon a commercially avail-
able kit (Quantikine ELISA kit, R&D systems, MN, USA).29 The PK
parameters were calculated using non-compartmental methods that in-
cluded steady-state concentration (Css) and systemic clearance (CL). Css
was estimated using the serum concentration determined at 48 h, while
CL was estimated using the rate of infusion and Css for each patient.
Blood was collected on Day 1 (baseline) and post-dose on Day 30 for
assessment of immunogenicity. Serum anti-serelaxin antibody concen-
trations were evaluated using a validated four-tiered assay approach for
antibody screening, confirmation, titration, and neutralizing antibody de-
tection, when applicable.
2.7 Safety assessments
All adverse events (AEs) were recorded along with investigator-
reported seriousness, intensity, and relationship to study drug. Clinical
laboratory assessments (including haematology, biochemistry, and uri-
nalysis), physical examination, electrocardiograms, and vital signs were
assessed at Day 30 and Day 180.
2.8 Statistical analysis and sample size
calculation
The change from baseline in mean global MBF (at rest and stress) and
global MPR were analysed using analysis of covariance (ANCOVA) with
treatment as the classification factor and baseline as a covariate, and by
Bayesian approach assuming non-informative priors. The change from
baseline in AIx and PWV were analysed using a repeated measures
ANCOVA, including treatment, time, treatment by time, baseline by
time interactions, and baseline as fixed effects. Time was repeated within
each patient using an unstructured variance–covariance matrix. Adjusted
mean difference between groups was provided and corresponding 95%
confidence intervals (CIs) were calculated.
For the biomarker analyses, baseline was defined as the pre-dose as-
sessment on Day 1. Raw values as well as changes from baseline were
summarized by treatment and time. Descriptive statistics included
Figure 1 Study design and schedule for assessment of primary and secondary endpoints. AIx, augmentation index; CMR, cardiovascular magnetic reso-
nance imaging; EoS, end of study; h, hours; IV, intravenous; PWV, pulse wave velocity.
Effects of serelaxin on vascular function in CAD 3
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geometric mean and 95% CI. For geometric means of change from base-
line, a ratio to baseline was used to determine percentage change by first
calculating in the log domain and then back transforming using
exponentiation.
A priori power analysis indicated that data from 40 patients (20 per
treatment group), would provide 83% power provided the true increase
is at least 30%, or 64% power if the true increase is 25%. This estimate is
based on an assumed mean MPR 2.48 [standard deviation (SD) 0.65],
based on historical reference data. A sample size of 40 patients would
have 80% power to detect a clinically significant difference of 10% (in AIx
following 48 h serelaxin infusion) with a SD of 18 using a two-group
t-test, with a one-sided test at a significance level of 5%.
3. Results
3.1 Study population
A total of 62 patients were randomized to receive either serelaxin
(n= 32) or placebo (n= 30), of which 58 received the study drug (sere-
laxin, n= 30; placebo, n= 28) and were included in the safety analysis set.
Of 58 patients in the safety analysis set, 56 (97%) completed the study
until Day 180 (serelaxin, n= 29; placebo, n= 27), and 51 (88%) were in-
cluded in the primary outcome analysis (serelaxin, n= 25; placebo,
n= 26). The baseline characteristics of patients by treatment group are
provided in Table 1 and the study CONSORT diagram is shown in
Figure 2.
3.2 Primary endpoints
3.2.1 Myocardial perfusion endpoints
Compared with placebo, serelaxin infusion did not result in a significant
change in the co-primary endpoint of change in MPR from baseline to
47 h [-0.24 vs. -0.13, adjusted mean difference -0.11; (95% CI -0.4 to
0.18); P= 0.44]. No change was observed following serelaxin vs. placebo
in mean MBF during stress [-0.11 (95% CI -0.45 to 0.22); P= 0.76] or at
rest [0.06 (95% CI -0.06 to 0.18); P= 0.40], either globally or on an indi-
vidual left ventricular slice level (Figure 3 and Supplementary material on-
line, Tables S1–S3).
3.2.2 Augmentation index endpoints
Compared with the placebo group, no significant differences in AIx were
observed following serelaxin treatment at 47 h [3.49% vs. 0.04%, ad-
justed mean difference 3.45 (95% CI -2.04 to 8.95), P= 0.21]. No change
was observed following serelaxin vs. placebo at 2 h [serelaxin vs. placebo
adjusted mean difference -2.12 (95% CI -7.49 to 3.25); P= 0.43], 6 h
[-2.88 (95% CI -6.84 to 1.08); P= 0.15], 24 h [–0.84 (95% CI -5.38 to 3.7);
P= 0.71], 50 h [3.25 (95% CI -2.90 to 9.41); P= 0.29], 54 h [-0.98 (95% CI
-6.72 to 4.75); P= 0.73], Day 30 [-1.75 (95% CI -7.26 to 3.75); P= 0.52],
or Day 180 [-0.05 (95% CI -4.67 to 4.57); P= 0.98] (Figure 4 and
Supplementary material online, Tables S4 and S5).
3.3 Secondary endpoints
3.3.1 Aortic stiffness
Compared with the placebo group, treatment with serelaxin resulted in
no difference in PWV at 24 h [serelaxin vs. placebo adjusted mean differ-
ence -0.16 (95% CI -0.86 to 0.54); P= 0.65], 47 h [-0.34 (95% CI -1.24 to
0.56); P= 0.45], Day 30 [-0.06 (95% CI -0.97 to 0.86); P= 0.9], or Day
180 [0.12 (95% CI -0.83 to 1.06); P= 0.80] (Supplementary material on-
line, Figure S1 and Tables S6 and S7).
There was no significant change (P> 0.05 for all) from baseline to 47 h
in the serelaxin group compared with placebo in the CMR-derived
parameters of aortic stiffness (ascending aorta strain, ascending aorta dis-
tensibility, descending aorta strain, descending aorta distensibility, and as-
cending aortic peak flow velocity) (Supplementary material online, Figure
S2 and Tables S8A and B).
3.3.2 Left and right ventricular volumes and function
There were no statistically significant changes from baseline in the sere-
laxin group compared with placebo in the left and right ventricular vol-
umes and ejection fractions. The left ventricular ejection fraction
remained in the normal range (mean value 63%) with no significant
changes observed with serelaxin treatment (Supplementary material on-
line, Figures S3 and S4).
3.3.3 Pharmacodynamics
A summary of the biomarker analysis is shown in Supplementary mate-
rial online Table S9.
The geometric means of hsTnT at baseline were 7.6 ng/L in the sere-
laxin group and 7.1 ng/L in the placebo group. A statistically significant
decrease in hsTnT from baseline was observed following treatment with
serelaxin at 48 h (geometric mean ratio 0.87; 95% CI 0.79–0.95). No sta-
tistically significant change from baseline was observed with serelaxin at
24 h and 54 h or in the placebo group (P> 0.05).
The geometric means of cystatin C at baseline were 0.93 mg/L in the
serelaxin group and 0.87 mg/L in the placebo group. A statistically signifi-
cant decrease in cystatin C from baseline was observed following treat-
ment with serelaxin at 24 h (cystatin C geometric mean ratio 0.92; 95%
CI 0.89–0.94, 48 h (geometric mean ratio 0.93; 95% CI 0. 91–0.96), and
54 h (geometric mean ratio 0.87; 95% CI 0.80–0.94). The change in cysta-
tin C levels from baseline in the placebo group were not statistically sig-
nificant at 24 and 48 h, but a statistically significant change was observed
at 54 h (geometric mean ratio 0.95; 95% CI 0.91–0.99).
The geometric means of endothelin-1 at baseline were 0.874 pmol/L
in the serelaxin group and 0.771 pmol/L in the placebo group.
Endothelin-1 levels were significantly decreased from baseline in the ser-
elaxin group at 24 h (geometric mean ratio 0.82; 95% CI 0.68–0.99), 48 h
(geometric mean ratio 0.82; 95% CI 0.70–0.96), and 54 h (geometric
mean ratio 0.84; 95% CI 0.73–0.96). No statistically significant
endothelin-1 change from baseline was observed in the placebo group.
The geometric means of NT-proBNP at baseline were 87.0 pg/mL in
the serelaxin group and 81.5 pg/mL in the placebo group. NT-proBNP
levels were statistically significantly increased from baseline in the sere-
laxin group at 54 h (geometric mean ratio 1.36; 95% CI 1.06–1.75) to a
level of 117.1 pg/mL but were not statistically significantly changed at
24 h or 48 h. In the placebo group, NT-proBNP levels statistically signifi-
cantly decreased compared with baseline at 24 h (geometric mean ratio
0.78; 95% CI 0.69–0.88) and 48 h (geometric mean ratio 0.76; 95% CI
0.60–0.95) with no statistically significant change at 54 h.
3.3.4 Pharmacokinetics and immunogenicity
Following a 48 h IV infusion of serelaxin, geometric mean serum concen-
tration of serelaxin increased gradually from 24 to 48 h during the IV in-
fusion, followed by a rapid decline after the infusion stopped at 48 h
(Supplementary material online, Figure S5). Serelaxin serum concentra-
tions at 24 h were similar to those at 48 h (prior to end of infusion), indi-
cating that steady state was achieved. The geometric means for the
estimated Css and CL were 15.1 ng/mL and 83.0 mL/h/kg, respectively.
4 D. Corcoran et al.
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serelaxin antibody negative prior to dosing on Day 1 (baseline) and at
follow-up on Day 30.
3.3.5 Safety endpoints
After 2 and 6 h of serelaxin infusion, mean placebo-corrected blood
pressure reductions of approximately -9.6 mmHg (P= 0.01) and
-13.5 mmHg (P= 0.0003) for SBP and -5.2 mmHg (P= 0.02) and
-8.4 mmHg (P= 0.001) for diastolic blood pressure (DBP) were
observed (Supplementary material online, Figure S6 and Table S10). No
patient discontinued the study due to hypotensive events.
None of the AEs reported during this study (serelaxin, n= 17; pla-
cebo, n= 19) were considered to be causally related to serelaxin
(Supplementary material online, Table S11). The incidence of serious
AEs (SAEs) was similar between groups (serelaxin, n= 5; placebo, n= 7).
Three patients (serelaxin, n= 1; placebo, n= 2) experienced an SAE dur-
ing study drug infusion (all unstable angina). Two patients (serelaxin,
n= 1; placebo, n= 1) discontinued from the study drug infusion due to
an SAE (unstable angina and non-ST elevation myocardial infarction).
..............................................................................................................................................................................................................................
Table 1 Baseline characteristics
Serelaxin Placebo All patients (dosed)
(N5 30) (N5 28) (N5 58)
Demographics
Age (years) 63 ± 6 60 ± 7 61 ± 7
Male (%) 27 (90) 26 (93) 53 (91)
Ethnicity (%)
Caucasian 29 (97) 26 (93) 55 (95)
South Asian 1 (3) 1 (4) 2 (3)
Mixed ethnicity 0 (0) 1 (4) 1 (2)
Weight (kg) 90 ± 17 94 ± 15 92 ± 16
BMI (kg/m2) 30 ± 5 31 ± 4 30 ± 4
Medical history (%)
Angina pectoris 18 (60) 18 (64) 36 (62)
Myocardial infarction 6 (20) 8 (29) 14 (24)
LV systolic dysfunction 2 (7) 0 (0) 2 (3)
Hypertension 17 (57) 19 (68) 36 (62)
Diabetes mellitus 6 (20) 4 (14) 10 (17)
Percutaneous coronary intervention 0 (0) 2 (7) 2 (3)
Cardiovascular medications (%)
Anti-platelet drugs 30 (100) 28 (100) 58 (100)
Statin 29 (97) 28 (100) 57 (98)
Nitrate 26 (87) 25 (89) 51 (88)
Beta-blocker 25 (83) 24 (86) 49 (84)
ACEI 14 (47) 15 (54) 29 (50)
ARB 3 (10) 4 (14) 7 (12)
Diabetes medications (%)
Metformin 5 (17) 7 (25) 12 (21)
DPP-4 inhibitors 0 (0) 4 (14) 4 (7)
Insulin and analogues 6 (20) 0 (0) 6 (10)
Baseline NT-proBNPa (pg/mL) 87.0 (60.2–125.8) 81.5 (54.9–121.1) 84.4 (65.0–109.5)
Baseline CMR findingsb
LV EDV index (mL/m2) 82 ± 13 86 ± 16 84 ± 14
LV ESV index (mL/m2) 30 ± 8 32 ± 8 31 ± 8
LV mass index (g/m2) 39 ± 7 40 ± 9 39 ± 8
LV ejection fraction (%) 63 ± 5 64 ± 4 63 ± 4
RV EDV index (mL/m2) 71 ± 11 73 ± 12 72 ± 12
RV ESV index (mL/m2) 25 ± 4 26 ± 6 25 ± 5
RV ejection fraction (%) 65 ± 3 65 ± 4 65 ± 3
Patients with CMR LGE (%) 15 (30) 8 (29) 23 (40)
Data are presented as n (%) or mean ± SD where appropriate.
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CMR, cardiac magnetic resonance; DPP-
4, dipeptidyl peptidase 4; EDV, end-diastolic volume; ESV, end-systolic volume; LGE, late gadolinium enhancement; LV, left ventricular; NT-proBNP, N-terminal pro-brain natriuretic
peptide; RV, right ventricular; SD, standard deviation.
aData are presented as geometric mean (95% confidence intervals).
bThese values correspond to the primary endpoint analysis set (serelaxin, n= 25; placebo, n= 26).
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.A relationship between the event and the study medication was not sus-
pected. One placebo-treated patient had an SAE of moderate intensity
(type IV hypersensitivity reaction, allergic dermatitis), which was sus-
pected to be treatment related. The SAEs (angina pectoris, unstable an-
gina, acute myocardial infarction, angio-oedema, gastro-oesophageal
reflux, pleural effusion, vascular procedure-related complication, and
cardiac procedure-related complication) reported for the remaining
nine patients (serelaxin, n= 4; placebo, n= 5) were severe in intensity,
but not suspected to be study drug related. No deaths were reported
during this study.
4. Discussion
This study investigated the effects of serelaxin on coronary microvascu-
lar and systemic macrovascular function in patients with stable CAD, the
single most common comorbidity in patients with AHF.9–11 In this study,
48 h of intravenous serelaxin reduced blood pressure but did not alter
myocardial perfusion or aortic stiffness. Myocardial perfusion was main-
tained despite a reduction in arterial blood pressure, and serelaxin was
well-tolerated.
In contrast to RELAX-AHF and RELAX-AHF-2, we enrolled patients
with stable CAD and excluded patients with AHF at baseline or NYHA
Class III–IV HF at baseline. The presence of obstructive CAD leading to
ischaemia is an adverse prognostic factor in patients with AHF, as
reflected by elevated serum concentrations of troponin and worse clini-
cal outcomes.30 The benefits of IV serelaxin infusion that were observed
in the RELAX-AHF trial1 were considered to be potentially mediated
through improvements in myocardial perfusion leading to a reduction in
myocardial ischaemia in patients with AHF. Conversely, should an IV in-
fusion of serelaxin reduce arterial blood pressure in patients with
obstructive CAD, and if coronary autoregulation is insufficient, myocar-
dial perfusion may be reduced, potentially provoking harmful ischaemia.
No serelaxin-induced changes in coronary microvascular function
were observed. The observed stress-induced mean increase in global
MBF was 1 mL/g/min. This is lower in comparison to healthy control
cohorts and reflects the underlying CAD in the study population.31–33
The lack of effect of serelaxin on mean global MBF and MPR is consid-
ered to be scientifically interesting, particularly in light of previous obser-
vations with nitroprusside and dipyridamole,34,35 that have been
associated with reduced local myocardial perfusion, particularly in redis-
tribution of blood away from ischaemic regions of the heart.34,35
Aortic stiffness is associated with an increased risk of developing HF36
and is abnormal in patients with HF.37 In our study, parameters of macro-
vascular function measured with applanation tonometry (AIx and PWV)
and CMR (aortic distensibility, strain, and peak flow velocity) methods
revealed no change following treatment with serelaxin. However, fol-
lowing 2 and 6 h of serelaxin infusion, mean placebo-corrected blood
pressure reductions of approximately -9.6 and -13.5 mmHg for SBP, and
-5.2 and -8.4 mmHg for DBP were observed. No difference in SBP or
DBP was observed between 24 and 48 h post-infusion. These blood
pressure changes did not translate into detectable changes in MBF as
assessed by perfusion CMR.
We did not detect an improvement in MPR or AIx with the serelaxin
dose and duration 48 h administered in the RELAX-AHF and RELAX-
AHF-2 trials. The pathophysiological and haemodynamic mechanisms of
AHF may occur over many weeks. It is plausible that a 48 h serelaxin infu-
sion may be too short to recruit an effect on coronary microvascular
and systemic macrovascular function. Prior pre-clinical studies demon-
strating improved vascular function and anti-fibrotic benefits have used
prolonged dosing protocols.38–41 In our study, the mean left ventricular
ejection fraction was 63%, whereas it was 39% in the RELAX-AHF
Figure 2 Study CONSORT diagram. AE, adverse event; PD, pharmacodynamic; PK, pharmacokinetic. aOnly the patients who received serelaxin were
analysed and included in the PK analysis set.
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Figure 3 Absolute values of myocardial perfusion assessments at baseline and 47 h post-randomization in serelaxin vs. placebo groups. The box plots of
the myocardial perfusion assessments were based on 51 patients (serelaxin, n= 25; placebo, n= 26) who were included in the pharmacodynamic analysis.
(A) mean global rest MBF (B) mean global stress MBF (C) global MPR (D) mid segment rest MBF (E) mid segment stress MBF (F) mid segment MPR. h, hours;
MBF, myocardial blood flow; MPR, myocardial perfusion reserve. Global MBF represents the mean MBF from all 16 American Heart Association (AHA) seg-
ments. Mid-MBF represents the mean MBF from the six mid-level left ventricular segments. The horizontal line in the box interior represents the median,
while the symbol in the box interior represents the mean. Values outside the whiskers are identified with symbols and are extreme values. The
upper (lower) edge of the box represents the 75th (25th) percentile. A whisker is drawn from the upper (lower) edge of the box to the largest (smallest)
value within 1.5 interquartile range above (below) the edge of the box.
Figure 4 Absolute values of augmentation index in the serelaxin vs. placebo groups at study time points. The box plots of the augmentation index assess-
ments were based on 51 patients (serelaxin, n= 25; placebo, n= 26) who were included in the final analysis. AIx, augmentation index; D, days; h, hours. The
horizontal line in the box interior represents the median, while the symbol in the box interior represents the mean. Values outside the whiskers are identi-
fied with symbols and are extreme values. The upper (lower) edge of the box represents the 75th (25th) percentile. A whisker is drawn from the upper
(lower) edge of the box to the largest (smallest) value within 1.5 interquartile range above (below) the edge of the box.
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cohort, reflecting the different populations enrolled, and it is plausible
that this may have influenced the results. Finally, the neutral result may
be attributed in part to the effects of baseline vasodilating medications in
this specific patient population. The PK analysis provides supporting evi-
dence that the lack of an effect of serelaxin on MPR and AIx is not due to
a lack of PK exposure. The RXFP1 has been demonstrated in cardiac tis-
sue and cardiomyocytes.19,42,43 Consistent with previous observations,
typical serum PK serelaxin concentrations (an additional quality control
measure) were observed over the 48 h infusion period, with steady-
state achieved between 24 and 48 h, with a rapid decline post-infusion
thereafter.44,45
No clinically relevant change from baseline in hsTnT was observed in
either treatment group, supporting myocardial safety in both treatment
groups. A significant reduction in hsTnT was observed following 48 h
serelaxin infusion vs. placebo, although levels were still considered to be
in the normal range and this difference did not persist at 54 h. The cysta-
tin C reductions observed with serelaxin at 24, 48, and 54 h are consis-
tent with the renal benefit previously observed in patients with AHF.46
The reduction in endothelin-1 with serelaxin at 24, 48, and 54 h suggests
beneficial effects on vascular function, consistent with improvement in
biomarkers related to cardiac, renal, and hepatic damage previously ob-
served in patients with AHF.46 These observations reflect the mecha-
nism of action of serelaxin, which has been shown to increase
expression of the endothelin B receptor, thereby acting as a sink to
endothelin-1.47 There was a small but statistically significant increase in
NT-proBNP from baseline to 54 h in the serelaxin group. No significant
changes were observed at any other time points and the clinical rele-
vance of this finding is uncertain.
The safety observation period in this study following the 48 h infusion
extended until Day 180. No deaths occurred during the study period,
and the numbers of SAEs reported in each treatment group were similar.
The frequency and intensity of AEs were comparable between groups,
with no new safety findings identified for serelaxin.
This study is limited in that myocardial relaxin receptor (RXFP1) ex-
pression remains unknown in patients with cardiovascular disease, leav-
ing the potential to improve myocardial perfusion uncertain. CMR
imaging was performed on different types of MRI scanners and field
strengths across participating centres, implying some differences in mea-
surement sensitivity in dynamic imaging of myocardial perfusion.
However, this CMR measurement limitation is not supported by the ob-
servation of stable resting blood flow measurements in both placebo-
and serelaxin-treated groups. The left ventricular haemodynamic data
were consistent across sites and field strengths and any potential varia-
tions in analyses were controlled by central blinded reading. The meth-
ods of image analysis were the same, independent of MRI scanner type.
We assessed the effects of serelaxin on myocardial perfusion during sys-
temic hyperaemia induced by IV infusion of adenosine. Serelaxin acts via
an endothelial-dependent mechanism that is distinct from adenosine,
which acts via an endothelial-independent mechanism.48 We cannot dis-
count the possibility that the effect of serelaxin on myocardial perfusion
with adenosine pharmacological stress may have been blunted, and
therefore, we may have had limited sensitivity to detect any treatment
effect. We assessed global MBF by CMR imaging and did not align the
myocardial perfusion data with the perfusion territory of the major epi-
cardial coronary arteries. Investigating the effect of serelaxin on myocar-
dial perfusion in myocardial segments subtended by a coronary artery
with a flow-limiting stenosis compared to segments with normal epicar-
dial blood flow may have been informative.
In conclusion, intravenous administration of serelaxin (30mg/kg/day)
for 48 h in patients with stable CAD did not affect myocardial perfusion
or aortic stiffness, despite a mild lowering of SBP. No clinically relevant
changes were observed with serelaxin for NT-proBNP or hsTnT.
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